Carna Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Carna Biosciences has a total shareholder equity of ¥3.5B and total debt of ¥118.0M, which brings its debt-to-equity ratio to 3.4%. Its total assets and total liabilities are ¥3.9B and ¥377.0M respectively.
Key information
3.4%
Debt to equity ratio
JP¥118.00m
Debt
| Interest coverage ratio | n/a |
| Cash | JP¥3.16b |
| Equity | JP¥3.52b |
| Total liabilities | JP¥377.00m |
| Total assets | JP¥3.89b |
Recent financial health updates
Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Apr 11
Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Dec 26
Recent updates
What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You
Apr 17Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Apr 11How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?
Feb 17Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Dec 26Financial Position Analysis
Short Term Liabilities: 4572's short term assets (¥3.7B) exceed its short term liabilities (¥273.0M).
Long Term Liabilities: 4572's short term assets (¥3.7B) exceed its long term liabilities (¥104.0M).
Debt to Equity History and Analysis
Debt Level: 4572 has more cash than its total debt.
Reducing Debt: 4572's debt to equity ratio has reduced from 72.1% to 3.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4572 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4572 has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 17.7% each year.